To Get more Insights,  Request A Free Sample 

Global Hypertension Prevalence and Valsartan Patient Population: Market Demand Analysis

As per WHO, Approximately 1.4 billion adults aged 30–79 years worldwide are living with hypertension as of 2024, representing about 33% of the global population in that age range. However, only about 320 million adults (23%) have their blood pressure under control, while an estimated 600 million (44%) remain unaware they have the condition.

Valsartan Patient Population

As per available evidence, millions are taking the valsartan medication worldwide.

United States: In 2017, before the 2018 recall, approximately 1.9 million patients were prescribed Valsartan, with roughly 9.2 million total prescriptions dispensed. Following the NDMA contamination crisis in July 2018, U.S. prescriptions dropped sharply to around 4.2 million in 2019 as patients switched to alternative ARBs.

Global ARB Market Share: Among angiotensin receptor blockers, Valsartan market represented 18.4% of all ARB use in the USA, 16.3% in Canada, 3.1% in the UK, and just 1% in Denmark prior to the 2018 recall. Global Valsartan utilization decreased by approximately 15.7% following the recall, with significant patient migration to Losartan and other ARBs.

Regional Variations: In countries with over 10.8 million ARB users (USA), 3.3 million (UK), and 1.8 million (Canada), Valsartan accounted for varying market shares based on local prescribing preferences and formulary restrictions.

​The transition to generic Sacubitril/Valsartan combinations is expected to significantly expand the patient base consuming Valsartan-based therapies through 2026 and beyond.

Which High-Level Trends Matter Most for C-Suite Stakeholders in the Valsartan Market?

For investors and strategic planners, three granular trends are shaping the P&L of major pharmaceutical entities:

1. The "Entresto" Pivot: The July 2025 patent expiry of Novartis’s blockbuster heart failure drug Entresto is the single largest volume driver for Valsartan API. Generic approvals for Sacubitril/Valsartan (held by players like Lupin, Teva, and Zydus) will trigger a spike in Valsartan API consumption, estimated to rise by 12-15% globally in the first year of generic launch.
2. China-Plus-One is Real but Slow: While Indian manufacturers like Aurobindo and Jubilant are expanding capacity in the valsartan market, they remain 40-60% dependent on China for the Key Starting Material (KSM), 2-Cyano-4-methylbiphenyl (OTBN). True supply chain independence remains elusive.
3. Regulatory CAPEX Spikes: The implementation of mandatory Risk Assessments for nitrosamine impurities (NDMA/NDEA) by the FDA and EMA has permanently raised the Cost of Goods Sold (COGS). Manufacturers have been forced to invest heavily in LC-MS/MS analytical equipment, creating a barrier to entry for smaller, non-compliant API players.

What Top 3 External Threats Could Disrupt the Valsartan Market’s Growth Story?

1. Newer ARBs: While Valsartan is popular, Telmisartan and Olmesartan offer longer half-lives. If guidelines shift to prefer these newer "Sartans," Valsartan could lose first-line status.
2. Clinical Guideline Changes: If the American College of Cardiology (ACC) updates guidelines to favor SGLT2 inhibitors over ARBs for initial heart failure treatment, the projected volume growth from the "Entresto" generics could be dampened.
3. Geopolitics: A trade war between the West and China could be catastrophic. Since ~70% of the world's OTBN comes from China, tariffs or export bans would cripple Indian and European formulators instantly.

How Has the NDMA Impurity Crisis Reshaped Market Resilience?

The discovery of N-nitrosodimethylamine (NDMA) in Valsartan APIs supplied by Zhejiang Huahai in 2018 was a watershed moment for the Valsartan market. It did not just cause recalls, it fundamentally altered the procurement criteria of Western pharmaceutical giants.

• Market Share Redistribution: Post-crisis, major share shifted from tainted suppliers to firms with "clean" chemistry routes (e.g., those avoiding the use of contaminated solvents like DMF in the tetrazole ring formation step).
• The "Clean Label" Premium: Manufacturers who can certify their API as "Nitrosamine-Free" via rigorous batch testing now command a 5-10% price premium in regulated markets (US/EU).
• Litigation Impact: The ongoing multi-district litigation in the US continues to pressure the margins of generic firms, forcing them to hold higher liability insurance reserves, which indirectly impacts net profitability.

What Regulatory Barriers Are Redefining Valsartan Market Entry?

The entry "channel" around the Valsartan market is no longer intellectual property, it is regulatory compliance.

• USP/EP Divergence: The United States Pharmacopeia (USP) and European Pharmacopoeia (EP) have harmonized on strict limits for nitrosamines (often <30 ppb). However, the method of testing differs, forcing global API exporters to maintain dual-compliance testing protocols.
• The "Risk Assessment" Mandate: Every Abbreviated New Drug Application (ANDA) filer must now submit a comprehensive risk assessment detailing the potential for nitrosamine formation at every step of synthesis. This has extended the approval timeline for new generic entrants by approximately 4-6 months.
• Audit Intensity: The FDA has ramped up unannounced inspections in India and China, specifically targeting facilities producing "Sartan" APIs. A single Warning Letter regarding impurity controls can now lead to immediate import alerts, effectively locking a player out of the US market for 12-24 months.

Where Are the Shifts in API Supply Chain and KSM Sourcing an What is its Impact on the Market?

The supply chain for Valsartan market is a story of asymmetric dependency. For instance, the OTBN Choke Point. The synthesis of Valsartan relies heavily on 2-Cyano-4-methylbiphenyl (OTBN). As of 2024, China controls over 65% of the global OTBN capacity. Major suppliers include Zhejiang Tianyu and Shandong Holly.

• Pricing Volatility: OTBN prices have shown volatility, fluctuating between $50−60/kg depending on crude oil derivatives and environmental crackdowns in Chinese industrial parks.
• Indian Backward Integration: To mitigate this, Indian giants like Lupin and Aurobindo have initiated CAPEX cycles to manufacture OTBN domestically. However, the cost advantage still lies with China due to economies of scale.

API Spot Prices in the Valsartan Market:

• US Delivered: ~$75,000 - $91,000 per Metric Ton (MT).
• China FOB: ~$75,000 - $83,000 per MT.

However, the prices softened in late 2024 due to inventory clearance, but are expected to stabilize as demand from generic Entresto manufacturers kicks in.

How Fast Will the Valsartan Market Grow Through 2035?

While the valsartan market is mature, it is not stagnant. Astute Analytica project revenue growth at a CAGR of 7.50%, but volume growth will likely exceed 6.5%. The disparity is due to the "price erosion" inherent in generic markets.

The analysis further finds that a sharp spike in volume is likely to have strong impact for Q3 2025 and throughout 2026. This correlates directly with the launch of generic Sacubitril/Valsartan.

Moreover, the valsartan market will likely split by 2030. Wherein, "Commodity Valsartan" (monotherapy) will see flat revenues, while "Complex Valsartan" (FDCs) will drive 80% of the value growth.

Why Are Fixed-Dose Combinations (FDCs) Outpacing Monotherapy?

Today, physicians are increasingly moving away from monotherapy for hypertension, favoring Fixed-Dose Combinations (FDCs) for better patient compliance.

• Valsartan + Amlodipine: The standard of care for Stage 2 hypertension. This segment is growing at roughly 6% YoY.
• Valsartan + Hydrochlorothiazide (HCTZ): A mature segment with slow growth, largely purely demographic-driven.
• The "Entresto" Effect: Technically a supramolecular complex, the Sacubitril/Valsartan combination is the star performer. With the patent wall falling, this specific FDC will likely become the most prescribed heart failure medication globally, significantly increasing the total tonnage of Valsartan API required annually.

How Are Distribution Channels Evolving for Chronic Care Drugs in Valsartan Market?

In the US, the "Big Three" retailers (CVS, Walgreens, Rite Aid) alongside PBMs (Pharmacy Benefit Managers) exert massive pressure on generic manufacturers. This forces manufacturers to bid on razor-thin margins to secure volume contracts.

• Online Pharmacies: In APAC and Europe, online prescription fulfillment for chronic maintenance drugs like Valsartan is growing at 15% YoY. Patients prefer 90-day supply shipments, which favors larger packaging formats and streamlined logistics.
• Hospital Tenders: In markets like the UK and Germany, distribution is dictated by regional tenders. Winning a tender guarantees volume but caps profit margins significantly.

What Drives Pricing and Demand in the North American Valsartan Market?

North America remains the largest value market, capturing approximately 38% of global revenue, but it is also the most brutal regarding pricing, especially across the US. Wherein, Group Purchasing Organizations (GPOs) like Vizient and Premier control hospital sourcing prioritize "Supply Security" over rock-bottom pricing post-COVID, favoring manufacturers with redundant supply chains (e.g., sites in both India and the US).

• ImportAlert Sensitivity: The US valsartan market is highly sensitive to FDA import alerts. When a major Indian supplier receives a 483 observation, spot prices in the US can jump 20% overnight as buyers scramble for alternative stock.
• Generic Entresto Launch: The FDA has already tentatively approved generics from Lupin, Aurobindo, and Teva. The battle for the "180-day exclusivity" or "First-to-File" status will determine who captures the lion's share of the early profits in late 2025.

How Do Tender Systems and VBP Policies Affect Europe and APAC Market?

China's VBP (Volume-Based Procurement): 

This is the single biggest disruptor in Asia Pacific valsartan market. The National VBP rounds have slashed the price of Valsartan generics by over 60%.

• Impact: Only manufacturers with massive scale (vertical integration from KSM to Finished Dose) can survive. Smaller Chinese players have exited the domestic market and are dumping capacity on the export market, depressing global API prices.

Europe's Tender Model: 

Germany’s AOK tenders are "winner-take-all." This leads to periodic shortages. If the winning bidder faces a manufacturing hiccup (e.g., a nitrosamine flag), the entire country faces a stockout. This has led EU regulators to discuss "multi-winner" tenders to ensure security of supply.

Competitive Landscape: Which Top 5 Players Dominate the Global Market Share?

The valsartan market is effectively an oligopoly of vertically integrated giants.

1. Novartis (Innovator): Still holds share via Diovan and Entresto, but facing inevitable decline in the face of generics.
2. Teva Pharmaceutical (Israel): A dominant player with a robust global supply chain and "clean" API sources.
3. Lupin Limited (India): A key aggressor. Their massive investment in Florida and expanded capacity in India positions them to lead the US generic market, especially for the upcoming Entresto generic.
4. Zhejiang Huahai (China): Despite the 2018 crisis, they remain a volume giant. They have heavily invested in remediation and "Green Chemistry" to regain trust, and they remain a critical supplier for non-regulated markets.
5. Aurobindo Pharma (India): The volume leader. Known for aggressive pricing and massive backward integration capabilities.

What Top 3 Factors Are Influencing Cost Structures and Margin Dynamics of the Valsartan Market Growth?

1. Raw Material Costs (60% of COGS): The cost of OTBN and Sodium Azide drives the base cost. Recent softening in chemical prices in China has helped margins slightly in 2024.
2. Compliance Costs (15% of COGS): The new normal. Frequent batch testing for nitrosamines using LC-MS/MS is expensive. This cost cannot easily be passed on to customers in a price-capped environment.
3. Freight & Logistics: Rates have stabilized post-2022, but geopolitical tensions (Red Sea route) pose a risk for Indian exports to Europe, potentially adding $2−3 per kg in landed costs.

Analyst’s Recommendation: Where Should Investors and Manufacturers Focus for Max ROI ?

• For API Manufacturers: Backward Integration is non-negotiable. Relying on Chinese OTBN is a strategic vulnerability in the valsartan market. Investments should focus on building domestic capacity for 2-Cyano-4-methylbiphenyl and Sodium Azide.
• For Generic Formulators: Chase the Combination. Do not launch plain Valsartan. The money is in the Sacubitril/Valsartan generic. Securing a "First-to-File" or at least a "First-Wave" launch is critical for ROI.
• For Investors: Look for companies with "Dual-Source" filings. A generic manufacturer that lists both an Indian and a European API supplier in their dossier is far more valuable than one relying solely on a single source, as they are insulated from regulatory shockwaves.

Segmental Analysis of the Valsartan Market

By Formulation, Why Monotherapy Formulations Held a ~51% Share of Valsartan Market in 2025

This figure is deceptive. While 51% appears to be a majority, it represents a market largely in decline. In 2020, monotherapy share was significantly higher. The slide to 51% indicates that clinical preference has shifted.

• The FDC Takeover: Clinical guidelines (ACC/AHA and ESC) now aggressively recommend dual therapy (e.g., Valsartan + Amlodipine) as a starting treatment for Stage 2 hypertension.
• The "Entresto" Cliff: The most critical insight for 2026 is that the monotherapy share will likely drop below 50% within 18 months. As generic Sacubitril/Valsartan floods the market following the July 2025 patent expiry, prescriptions will mass-migrate from standalone Valsartan to this heart failure FDC, which offers superior mortality outcomes. Investors should view "Plain Valsartan" as a cash cow, but "Valsartan Combinations" as the star.

By Dosage Strength, 81-160 mg Captured the Highest Market Share (~45%) in 2025.

This data validates the standard of care protocols. The "Maintenance" Dose— 80mg and 160mg—is the target maintenance doses for hypertension. The 40mg dose is primarily an initiation dose for heart failure, while 320mg is reserved for resistant hypertension.

For producers in the valsartan market, this dictates inventory strategy. Production lines should be optimized for 160mg tablets, which offer the best balance of API usage efficiency and pricing tiers. The demand for 80mg/160mg is inelastic; patients cannot easily switch off these doses without clinical risk, providing a stable revenue floor for manufacturers.

By Indication, Why Does Hypertension Remain the Primary Revenue Driver?

The hypertension segment generated the biggest market share (~52%) in valsartan market. While Heart Failure (HF) is the high-growth niche, Hypertension remains the volume beast.

• Chronic Management: Hypertension therapy is lifelong. A patient diagnosed at 50 will consume Valsartan daily for 30+ years. This creates a predictable recurring revenue model (ARR) that few other industries enjoy.
• The "Silent Killer" Awareness: Post-COVID, there has been a global surge in cardiovascular screening. The diagnosis rate for hypertension has improved significantly in developing markets (Brazil, Indonesia, Vietnam), feeding directly into the 52% share.

While Heart Failure applications will grow faster (due to the Entresto generic boom), Hypertension will remain the dominant volume driver of the valsartan market simply due to the massive global patient population size (estimated at 1.3 billion people worldwide).

By Product Type, How Are Supply Chain Economics Favoring Finished Dosage Forms (FDFs)?

Based on product type, Finished Dosage Forms (FDFs) contributed the highest market share (~62%) to valsartan market in 2025. The 62/38 split between FDFs and Active Pharmaceutical Ingredients (APIs) highlights a critical value-add dynamic. While APIs constitute the biological backbone, the profit margins reside in the FDFs.

• Vertical Integration Wins: The dominance of FDFs indicates that companies with vertical integration (manufacturing both the API and the finished pill) are capturing the majority of the market value. Standalone API manufacturers are being squeezed by commoditization, whereas FDF manufacturers control the branding and distribution relationships.
• Export Dynamics: India’s role as the "Pharmacy of the World" is central here. The surge in Abbreviated New Drug Application (ANDA) approvals for Indian firms to ship finished Valsartan tablets to the US and EU contributes significantly to this 62% share.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis: Why Does North America Retain Value Dominance in Valsartan Market While APAC Explodes in Volume?

North America Captured the Largest Market Share (~38%) in 2025

The dominance of North America, particularly the United States, is a function of pricing structures, not necessarily consumption volume. While prescription volumes for Angiotensin II Receptor Blockers (ARBs) are high, the dollar value is sustained by the residual pricing power of branded generics and the high reimbursement rates within the Medicare Part D and commercial insurance frameworks.

• The Pricing Paradox: Despite the patent expiry of Diovan years ago, the US market sustains higher Average Selling Prices (ASPs) compared to the rest of the world. This is driven by the consolidation of Group Purchasing Organizations (GPOs) like Vizient and Premier, which prioritize "supply reliability" over rock-bottom pricing—a lesson learned hard during the 2018-2019 impurity shortages.
• The Entresto Factor: The 38% share in the valsartan market is also heavily skewed by the revenue contribution of Sacubitril/Valsartan (Entresto). As of 2025, the US remained the most lucrative market for this blockbuster, inflating the overall "Valsartan-related" revenue figures before the full onset of generic erosion in late 2025/early 2026.

Asia-Pacific is Expected to Grow at the Fastest CAGR of ~8.1% in Global Valsartan Market

The regional growth rate—nearly double the global pharmaceutical average—signals a massive epidemiological and industrial shift. The sheer rise in geriatric populations in China (projected 400M+ over 60 by 2035) and India drives this strong demand momentum. Wherein, hypertension is no longer a "Western" disease, it is the primary comorbidity in developing APAC economies.

The growth is also supply-side driven. China and India are no longer just exporting, they are consuming. In addition, omestic procurement policies, such as China’s Volume-Based Procurement (VBP), have made Valsartan accessible to millions of new patients, driving volume growth even as unit prices drop.

Top 5 Strategic Developments Announced by Players in Valsartan Market 

1. Lupin FDA Approval: In January 2025, Lupin Limited announced it received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Sacubitril and Valsartan tablets (24/26mg, 49/51mg, and 97/103mg), positioning it as a key generic competitor.
2. Novartis Patent Litigation Setback: In July 2025, a U.S. federal judge rejected Novartis's bid to block MSN Pharmaceuticals from launching a generic version of Entresto, ruling that the generic did not infringe on a key combination patent.
3. Aurobindo China Expansion: Aurobindo Pharma supercharged its China operations in late 2025 by acquiring an additional 20% stake in its Chinese joint venture, aiming to boost manufacturing capacity and achieve economies of scale for global supply.
4. MSN Settlement: In June 2025, Novartis and MSN Pharmaceuticals reached a partial settlement in their long-running patent feud, though litigation continued over other specific patents related to the heart-failure medication.
5. Viatris Portfolio Growth: Viatris reported several regulatory milestones in late 2025, emphasizing its strategy to expand its complex generics portfolio as it navigates the competitive "Sartan" landscape following key patent cliffs.

Top Companies in the Valsartan Market

• Alembic Pharmaceuticals Limited
• AstraZeneca plc
• Aurobindo Pharma Limited
• Dr Reddy's Laboratories Ltd.
• Glenmark Pharmaceuticals Inc.
• Hetero Labs Limited
• Lupin Pharmaceuticals Ltd.
• Mylan N.V.
• Novartis AG
• Others
• Sandoz International GmbH
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries Ltd
• Torrent Pharmaceuticals Limited
• Zydus Cadila
• Other Prominent Players

Market Segmentation Overview

By Product Type

• Valsartan API
• Finished Dosage Forms (FDFs)
  • Tablets
  • Fixed-dose combinations

By Formulation

• Monotherapy Formulations
• Combination Formulations

By Dosage Strength

• ≤ 80 mg
• 81–160 mg
• > 160 mg

By Indication

• Hypertension
• Heart Failure
• Post-Myocardial Infarction
• Other Cardiovascular Conditions

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Other Channels

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America